knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 23:59:34 - browse：28415

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Methadone treatment changes are coming. Do they go far enough?

explore

entertainment

WSS

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

The PBM ad wars are taking over Washington, D.C.

House panel to mark up pandemic

U.K. researchers warn about biases in medical devices, algorithms

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

AstraZeneca to buy developer of next

focus

knowledge

Wikipedia

How one medical school became remarkably diverse

Asbestos, a deadly carcinogen, banned by EPA

Dobbs anniversary: the lost opportunity of abortion as health care

Titanic submersible: What a 'catastrophic implosion' means and what officials found

Hepatitis C has a cure — but many Americans still lack access to it

Creating egg and sperm cells from stem cells raises ethical issues

New air purifier tech could be key to improving indoor air quality

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

Psychedelics group wrestles with new pharma identity

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

hotspot

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Florida group launches initiative to get abortion constitutional amendment on 2024 ballot

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

North Korean leader's powerful sister says warplanes repelled US spy plane

With fresh data, a dynamic duo powers Eli Lilly to new heights

The PBM ad wars are taking over Washington, D.C.

explore

focus

entertainment

hotspot